Jubilant Pharma completes studies using Remdesivir

New Delhi: Jubilant Pharmova on Monday said its arm Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of Covid-19 against the available injectable formulation of the antiviral drug in India.

Jubilant Pharma has successfully completed "safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir against the commercially available injectable formulation of Remdesivir," Jubilant Pharmova said in a filing to BSE.

Jubilant has sought authorisation for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI), it added. "Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for Covid-19 patients.

The proposed oral treatment is expected to be for five days, duration similar to the injectable dosage form," Jubilant Pharmova said. Remdesivir is the first and the only anti-viral drug fully approved by the USFDA for the treatment of patients with Covid-19 requiring hospitalisation, it added.